Serge Belanger Analyst Performance

Senior Analyst at Needham & Company LLC

Serge Belanger is a stock analyst at Needham & Company LLC focused in the healthcare sector, covering 25 publicly traded companies. Over the past year, Serge Belanger has issued 76 stock ratings, including buy and hold recommendations. While full access to Serge Belanger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Serge Belanger's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access to unlock analyst rankings MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 219 Last 11 Years
Buy Recommendations: 88.58% 194 Buy Ratings
Companies Covered: 25 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	88.6%	194 ratings
Hold	11.4%	25 ratings
Sell	0.0%	0 ratings

Out of 219 total stock ratings issued by Serge Belanger at Needham & Company LLC, the majority (88.6%) have been Buy recommendations, followed by 11.4% Hold.

Best & Worst Calls

Best Call
0000.0%
LQDA
May 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
0000.0%
CRXTQ
Mar 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.0% of companies on NASDAQ	22 companies
NYSE	8.0% of companies on NYSE	2 companies
OTCMKTS	4.0% of companies on OTCMKTS	1 company

Serge Belanger, an analyst at Needham & Company LLC, currently covers 25 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Healthcare 24 companies	96.0%
	Finance 1 company	4.0%

Serge Belanger of Needham & Company LLC specializes in stock coverage within the Healthcare sector, with additional focus on Finance companies.

Coverage Industries

Industry	Percentage
PHARMACEUTICALS 15 companies	60.0%
BIOTECHNOLOGY 9 companies	36.0%
CAPITAL MARKETS 1 company	4.0%

About Serge Belanger

Serge Belanger joined Needham & Company in 2009, where he covers the Biotechnology sector. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge was part of Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

0 Results

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
PCRX Pacira BioSciences	10/8/2026	Downgrade	$36.29		Hold
LQDA Liquidia	10/1/2026	Lower Price Target	$30.26	$72.00	Buy
OCUL Ocular Therapeutix	9/29/2026	Reiterated Rating	$7.66	$18.00	Buy
XENE Xenon Pharmaceuticals	9/18/2026	Lower Price Target	$57.35	$60.00	Buy
BCRX BioCryst Pharmaceuticals	9/8/2026	Reiterated Rating	$9.25	$16.00	Buy
EVMN Evommune	8/26/2026	Initiated Coverage	$13.79	$28.00	Buy
LQDA Liquidia	8/12/2026	Boost Price Target	$79.07	$110.00	Buy
CYTK Cytokinetics	8/7/2026	Boost Price Target	$80.22	$112.00	Buy
ARQT Arcutis Biotherapeutics	8/6/2026	Boost Price Target	$27.10	$40.00	Buy
COLL Collegium Pharmaceutical	8/6/2026	Lower Price Target	$29.23	$46.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
PCRX Pacira BioSciences	8/5/2026	Boost Price Target	$27.62	$33.00	Buy
MANE Veradermics	7/15/2026	Boost Price Target	$128.74	$164.00	Buy
VRDN Viridian Therapeutics	6/29/2026	Reiterated Rating	$17.90	$32.00	Buy
CYTK Cytokinetics	6/17/2026	Reiterated Rating	$75.21	$102.00	Buy
HRTX Heron Therapeutics	6/2/2026	Downgrade	$0.45		Hold
MANE Veradermics	6/2/2026	Initiated Coverage	$101.96	$136.00	Buy
OCS Oculis	6/1/2026	Lower Price Target	$22.70	$38.00	Buy
TRVI Trevi Therapeutics	5/20/2026	Reiterated Rating	$13.77	$23.00	Buy
MLTX MoonLake Immunotherapeutics	5/12/2026	Boost Price Target	$18.84	$30.00	Buy
OCS Oculis	5/12/2026	Boost Price Target	$30.40	$46.00	Buy
LQDA Liquidia	5/11/2026	Boost Price Target	$52.61	$70.00	Buy
XENE Xenon Pharmaceuticals	5/8/2026	Lower Price Target	$56.00	$78.00	Buy
AMPH Amphastar Pharmaceuticals	5/8/2026	Reiterated Rating	$24.03		Hold
ARQT Arcutis Biotherapeutics	5/7/2026	Reiterated Rating	$24.17	$36.00	Buy
TRVI Trevi Therapeutics	5/6/2026	Lower Price Target	$14.66	$23.00	Buy
BCRX BioCryst Pharmaceuticals	5/6/2026	Lower Price Target	$8.86	$16.00	Buy
VRDN Viridian Therapeutics	5/5/2026	Reiterated Rating	$18.77	$32.00	Buy
OCUL Ocular Therapeutix	5/5/2026	Reiterated Rating	$9.71	$18.00	Buy
CYTK Cytokinetics	5/5/2026	Boost Price Target	$77.20	$102.00	Buy
ESPR Esperion Therapeutics	5/4/2026	Downgrade	$3.12		Hold
PCRX Pacira BioSciences	5/1/2026	Boost Price Target	$25.49	$32.00	Buy
KALV KalVista Pharmaceuticals	4/30/2026	Downgrade	$26.66		Hold
CRMD CorMedix	4/27/2026	Boost Price Target	$7.54	$15.00	Buy
VRDN Viridian Therapeutics	3/30/2026	Lower Price Target	$18.52	$32.00	Buy
KALV KalVista Pharmaceuticals	3/25/2026	Boost Price Target	$17.14	$36.00	Buy
COLL Collegium Pharmaceutical	3/19/2026	Reiterated Rating	$36.30	$56.00	Buy
TRVI Trevi Therapeutics	3/18/2026	Boost Price Target	$11.19	$24.00	Buy
XENE Xenon Pharmaceuticals	3/9/2026	Boost Price Target	$61.46	$80.00	Buy
LQDA Liquidia	3/5/2026	Boost Price Target	$34.52	$54.00	Buy
CRMD CorMedix	3/5/2026	Lower Price Target	$6.30	$14.00	Buy
Your book attached (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes
OCS Oculis	3/4/2026	Boost Price Target	$27.57	$40.00	Buy
ESPR Esperion Therapeutics	3/3/2026	Boost Price Target	$2.94	$5.00	Buy
AMPH Amphastar Pharmaceuticals	2/27/2026	Lower Price Target	$26.49	$30.00	Buy
XENE Xenon Pharmaceuticals	2/27/2026	Boost Price Target	$42.23	$58.00	Buy
ARQT Arcutis Biotherapeutics	2/26/2026	Boost Price Target	$27.01	$36.00	Buy
COLL Collegium Pharmaceutical	2/26/2026	Lower Price Target	$44.01	$54.00	Buy
CYTK Cytokinetics	2/25/2026	Boost Price Target	$70.10	$85.00	Buy
LQDA Liquidia	2/25/2026	Reiterated Rating	$30.16	$52.00	Buy
MLTX MoonLake Immunotherapeutics	2/23/2026	Boost Price Target	$18.68	$25.00	Buy
OCUL Ocular Therapeutix	2/20/2026	Lower Price Target	$7.03	$18.00	Buy
NAMS NewAmsterdam Pharma	2/18/2026	Boost Price Target	$36.41	$48.00	Buy
VRDN Viridian Therapeutics	2/4/2026	Reiterated Rating	$31.90	$42.00	Buy
ARQT Arcutis Biotherapeutics	1/26/2026	Boost Price Target	$26.29	$31.00	Buy
PCRX Pacira BioSciences	1/9/2026	Reiterated Rating	$26.02	$30.00	Buy
CRMD CorMedix	1/8/2026	Lower Price Target	$7.51	$15.00	Buy
COLL Collegium Pharmaceutical	1/8/2026	Boost Price Target	$48.78	$56.00	Buy
KALV KalVista Pharmaceuticals	1/6/2026	Boost Price Target	$15.66	$32.00	Buy
EOLS Evolus	12/24/2025	Reiterated Rating	$6.81		Hold
VRDN Viridian Therapeutics	12/23/2025	Boost Price Target	$32.47	$42.00	Buy
CYTK Cytokinetics	12/22/2025	Boost Price Target	$62.72	$84.00	Buy
CYTK Cytokinetics	12/12/2025	Reiterated Rating	$60.77	$72.00	Buy
OCUL Ocular Therapeutix	12/8/2025	Reiterated Rating	$15.95	$20.00	Buy
KALV KalVista Pharmaceuticals	12/4/2025	Reiterated Rating	$14.66	$28.00	Buy
CLSD Clearside Biomedical	11/18/2025	Reiterated Rating	$3.32		Hold
CRMD CorMedix	11/12/2025	Lower Price Target	$11.17	$16.00	Buy
OCS Oculis	11/11/2025	Reiterated Rating	$19.42	$36.00	Buy
AMPH Amphastar Pharmaceuticals	11/7/2025	Lower Price Target	$24.23	$34.00	Buy
NAMS NewAmsterdam Pharma	11/5/2025	Boost Price Target	$39.84	$46.00	Buy
BCRX BioCryst Pharmaceuticals	11/4/2025	Lower Price Target	$6.86	$18.00	Buy
LQDA Liquidia	11/4/2025	Boost Price Target	$25.22	$52.00	Buy
XENE Xenon Pharmaceuticals	11/4/2025	Reiterated Rating	$41.12	$55.00	Buy
COLL Collegium Pharmaceutical	10/28/2025	Reiterated Rating	$34.81	$46.00	Buy
ARQT Arcutis Biotherapeutics	10/28/2025	Boost Price Target	$24.95	$30.00	Buy
AMPH Amphastar Pharmaceuticals	10/22/2025	Reiterated Rating	$24.26	$36.00	Buy
BCRX BioCryst Pharmaceuticals	10/15/2025	Boost Price Target	$6.42	$20.00	Buy
OMER Omeros	10/15/2025	Reiterated Rating	$10.94		Hold
OCUL Ocular Therapeutix	10/1/2025	Boost Price Target	$11.11	$20.00	Buy
MLTX MoonLake Immunotherapeutics	9/30/2025	Lower Price Target	$6.24	$20.00	Buy
KALV KalVista Pharmaceuticals	9/12/2025	Reiterated Rating	$13.60	$28.00	Buy
CYTK Cytokinetics	9/2/2025	Reiterated Rating	$35.33	$72.00	Buy
OCS Oculis	8/27/2025	Initiated Coverage	$17.53	$36.00	Buy
OMER Omeros	8/15/2025	Reiterated Rating	$4.12		Hold
AMPH Amphastar Pharmaceuticals	8/12/2025	Upgrade	$27.36	$36.00	Buy
LQDA Liquidia	8/12/2025	Boost Price Target	$24.10	$36.00	Buy
TRVI Trevi Therapeutics	8/8/2025	Lower Price Target	$7.30	$22.00	Buy
HRTX Heron Therapeutics	8/8/2025	Lower Price Target	$1.33	$3.00	Buy
ARQT Arcutis Biotherapeutics	8/7/2025	Boost Price Target	$15.36	$22.00	Buy
VRDN Viridian Therapeutics	8/6/2025	Lower Price Target	$17.22	$34.00	Buy
EOLS Evolus	8/6/2025	Reiterated Rating	$8.91	$22.00	Hold
OCUL Ocular Therapeutix	8/5/2025	Boost Price Target	$12.00	$15.00	Buy
Buffett's Final Warning: "The Dollar Is Going to Hell" (Ad) On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses. Watch how to protect yourself from what Dalio and Buffett see coming (free training).
BCRX BioCryst Pharmaceuticals	8/4/2025	Reiterated Rating	$8.73	$17.00	Buy
CLSD Clearside Biomedical	7/17/2025	Downgrade	$9.12	$45.00	Hold
BCRX BioCryst Pharmaceuticals	6/25/2025	Reiterated Rating	$9.78	$17.00	Buy
CRMD CorMedix	6/24/2025	Boost Price Target	$16.56	$20.00	Buy
NAMS NewAmsterdam Pharma	6/12/2025	Reiterated Rating	$20.50	$40.00	Buy
LQDA Liquidia	5/28/2025	Reiterated Rating	$15.60	$25.00	Buy
ARQT Arcutis Biotherapeutics	5/23/2025	Reiterated Rating	$13.66	$20.00	Buy
LQDA Liquidia	5/21/2025	Reiterated Rating	$17.02	$25.00	Buy
TRVI Trevi Therapeutics	5/20/2025	Reiterated Rating	$6.49	$24.00	Buy
VRDN Viridian Therapeutics	5/20/2025	Reiterated Rating	$13.25	$36.00	Buy
OMER Omeros	5/16/2025	Reiterated Rating	$3.95		Hold
CLSD Clearside Biomedical	5/15/2025	Lower Price Target	$12.81	$45.00	Buy
CYTK Cytokinetics	5/14/2025	Reiterated Rating	$30.61	$72.00	Buy
VRCA Verrica Pharmaceuticals	5/14/2025	Reiterated Rating	$0.50		Hold
XENE Xenon Pharmaceuticals	5/13/2025	Lower Price Target	$35.85	$55.00	Buy
MLTX MoonLake Immunotherapeutics	5/13/2025	Reiterated Rating	$40.18	$66.00	Buy
LQDA Liquidia	5/12/2025	Reiterated Rating	$15.93	$25.00	Buy
PCRX Pacira BioSciences	5/9/2025	Lower Price Target	$24.90	$30.00	Buy
EOLS Evolus	5/8/2025	Reiterated Rating	$11.80	$22.00	Buy
NAMS NewAmsterdam Pharma	5/8/2025	Lower Price Target	$19.50	$40.00	Buy
VRDN Viridian Therapeutics	5/7/2025	Lower Price Target	$12.03	$36.00	Buy
CRMD CorMedix	5/7/2025	Boost Price Target	$11.16	$15.00	Buy
ESPR Esperion Therapeutics	5/7/2025	Lower Price Target	$0.98	$4.00	Buy
BCRX BioCryst Pharmaceuticals	5/6/2025	Boost Price Target	$11.03	$17.00	Buy
CYTK Cytokinetics	5/2/2025	Reiterated Rating	$42.92	$72.00	Buy
MLTX MoonLake Immunotherapeutics	4/30/2025	Reiterated Rating	$40.18	$66.00	Buy
ESPR Esperion Therapeutics	4/25/2025	Reiterated Rating	$0.88	$5.00	Buy
HRTX Heron Therapeutics	4/11/2025	Reiterated Rating	$1.82	$4.00	Buy
BCRX BioCryst Pharmaceuticals	4/10/2025	Reiterated Rating	$6.77	$15.00	Buy
LQDA Liquidia	4/10/2025	Reiterated Rating	$12.77	$25.00	Buy
AMPH Amphastar Pharmaceuticals	4/10/2025	Reiterated Rating	$25.23		Hold
ARQT Arcutis Biotherapeutics	4/9/2025	Reiterated Rating	$13.29	$20.00	Buy
VRCA Verrica Pharmaceuticals	4/9/2025	Reiterated Rating	$0.58		Hold
EOLS Evolus	4/9/2025	Reiterated Rating	$9.36	$22.00	Buy
CRMD CorMedix	4/9/2025	Reiterated Rating	$6.79	$12.00	Buy
KALV KalVista Pharmaceuticals	4/8/2025	Reiterated Rating	$11.50	$28.00	Buy
TRVI Trevi Therapeutics	4/8/2025	Reiterated Rating	$5.78	$24.00	Buy
CYTK Cytokinetics	4/8/2025	Reiterated Rating	$35.99	$72.00	Buy
ESPR Esperion Therapeutics	4/8/2025	Reiterated Rating	$1.20	$5.00	Buy
CLSD Clearside Biomedical	4/8/2025	Reiterated Rating	$12.68	$60.00	Buy
NAMS NewAmsterdam Pharma	4/8/2025	Reiterated Rating	$15.86	$42.00	Buy
PCRX Pacira BioSciences	4/8/2025	Reiterated Rating	$22.91	$32.00	Buy
ARQT Arcutis Biotherapeutics	4/3/2025	Reiterated Rating	$16.60	$20.00	Buy
OMER Omeros	4/1/2025	Reiterated Rating	$8.27		Hold
CLSD Clearside Biomedical	3/28/2025	Lower Price Target	$15.45	$60.00	Buy
CRMD CorMedix	3/26/2025	Lower Price Target	$7.34	$12.00	Buy
KALV KalVista Pharmaceuticals	3/26/2025	Reiterated Rating	$12.07	$28.00	Buy
LQDA Liquidia	3/20/2025	Boost Price Target	$14.92	$25.00	Buy
TRVI Trevi Therapeutics	3/19/2025	Lower Price Target	$6.56	$24.00	Buy
KALV KalVista Pharmaceuticals	3/13/2025	Reiterated Rating	$12.45	$28.00	Buy
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad) A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. Click here to learn this company's name for free today
OCUL Ocular Therapeutix	3/11/2025	Initiated Coverage	$7.65	$15.00	Buy
TRVI Trevi Therapeutics	3/10/2025	Boost Price Target	$4.30	$25.00	Buy
CLSD Clearside Biomedical	3/6/2025	Reiterated Rating	$14.40	$90.00	Buy
EOLS Evolus	3/5/2025	Reiterated Rating	$14.35	$22.00	Buy
PCRX Pacira BioSciences	2/28/2025	Boost Price Target	$25.38	$32.00	Buy
HRTX Heron Therapeutics	2/28/2025	Reiterated Rating	$2.05	$4.00	Buy
MLTX MoonLake Immunotherapeutics	2/27/2025	Boost Price Target	$42.37	$66.00	Buy
ARQT Arcutis Biotherapeutics	2/26/2025	Reiterated Rating	$12.20	$20.00	Buy
CYTK Cytokinetics	2/6/2025	Reiterated Rating	$46.44	$72.00	Buy
EOLS Evolus	1/21/2025	Reiterated Rating	$13.87	$22.00	Buy
OMER Omeros	1/17/2025	Reiterated Rating	$9.18		Hold
BCRX BioCryst Pharmaceuticals	1/13/2025	Boost Price Target	$7.67	$15.00	Buy
PCRX Pacira BioSciences	1/13/2025	Boost Price Target	$20.64	$30.00	Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Serge Belanger Analyst Performance

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Serge Belanger

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Serge Belanger Analyst Performance

Analyst Rankings, Coverage, and Performance Statistics

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Serge Belanger

Serge Belanger's Ratings History at Needham & Company LLC

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools